Recombinant CD274 (Avelumab Biosimilar) 抗体
This anti-CD274 (Avelumab Biosimilar) antibody is a Humanized 单克隆 antibody detecting CD274 (Avelumab Biosimilar) in FACS 和 in vivo. Suitable for 人.
Quick Overview for Recombinant CD274 (Avelumab Biosimilar) 抗体 (ABIN7200665)
抗原
CD274 (Avelumab Biosimilar)
抗体类型
Recombinant Antibody
适用
人
宿主
Humanized
克隆类型
单克隆
标记
This CD274 (Avelumab Biosimilar) antibody is un-conjugated
应用范围
Flow Cytometry (FACS), In vivo Studies (in vivo)
质量等级
Research Grade
-
-
原理
- Avelumab Biosimilar, Human PD-L1 Monoclonal Antibody
-
特异性
- The in vivo grade avelumab biosimilar specifically binds to the programmed death ligand 1 (PD-L1), blocking its interaction with PD-1 and B7-1.
-
产品特性
- What is Avelumab biosimilar research grade? Avelumab is a humanized monoclonal antibody directed against the human protein ligand PD-L1 (B7-H1 or CD274, programmed cell death ligand 1), with potential antibody-dependent cell-mediated cytotoxicity property. Avelumab is used for the treatment of several kinds of carcinoma. Avelumab biosimilar uses the same protein sequences as the therapeutic antibody of Avelumab. PD-L1 (B7-H1 or CD274, programmed cell death ligand 1) and PD-L2 (B2-DC or CD273, programmed cell death ligand 2) are the two ligands for the receptor PD-1 (CD279, programmed death 1). PD-L1 is an immune checkpoint molecule expressed on both tumor cells and certain immune cells. The binding of PD-L1 to its receptors PD-1 or B7.1 on activated T cells causes an inhibitory signal to suppress their production in the lymph nodes, thereby preventing immune responses to events such as pregnancy or autoimmune disease. This pathway is also utilized by cancer cells to evade the immune system through evasion of anti-tumor T-cell response. Furthermore, over-expression of PD-L1 and PD-1 has been linked to increased tumor aggressiveness and poorer prognosis. Avelumab binds directly and selectively to PD-L1 and blocks interaction with both PD-1 and B7.1 receptors, thus reinvigorates and enhances the body's adaptive anti-cancer activity. Disrupting the PD-L1/B7.1 interaction may also enhance T-cell priming, which could result in increased duration of response and survival.
-
纯化方法
- Protein A or G affinity column
-
纯度
- >95 % by reducing SDS-PAGE
-
过滤
- 0.2 μm filtered
-
内毒素水平
- < 1 EU per 1 mg of the protein by the LAL method
-
免疫原
- The anti-human PD-L1 monoclonal antibody avelumab biosimilar was produced in the avelumab biosimilar Chinese Hamster Ovary (CHO) stable cell line.
-
亚型
- IgG1
-
-
-
-
应用备注
- ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by avelumab.
-
限制
- 仅限研究用
-
-
-
状态
- Liquid
-
浓度
- > 3 mg/mL
-
缓冲液
- PBS, pH 7.4, no stabilizers or preservatives.
-
储存液
- Without preservative
-
储存条件
- 4°C,-20 °C
-
储存方法
- 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
-
有效期
- 12 months
-
-
- CD274 (Avelumab Biosimilar)
-
别名
- Avelumab Biosimilar
-
物质类
- Biosimilar
抗原
-
You are here:
